Stockwatch

Date	Sym	Type	Headline
2025-07-01 08:31	UU:RSLS	News Release200	ReShape Lifesciences(TM) Granted U.S. Patent Related to an Intragastric Balloon System
2025-06-27 09:01	UU:RSLS	News Release200	ReShape Lifesciences(TM) Regains Compliance with Nasdaq Minimum Stockholders Equity Requirement
2025-06-26 08:31	UU:RSLS	News Release200	ReShape Lifesciences(TM) Announces Strategic Cost Reductions and Provides Update on the Merger Agreement with Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys
2025-06-25 08:31	UU:RSLS	News Release200	ReShape Lifesciences(TM) Granted Key International Patent in Australia for Its Proprietary Diabetes Neuromodulation Technology
2025-06-12 08:25	UU:RSLS	News Release200	ReShape Lifesciences(TM) Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD Markets
2025-06-09 09:00	UU:RSLS	News Release200	ReShape Lifesciences(TM) Announces Pricing of $2.6 Million Public Offering
2025-06-03 08:31	UU:RSLS	News Release200	ReShape Lifesciences(TM) Announces EU MDR Certification for Entire European and United Kingdom Product Portfolio
2025-05-21 08:31	UU:RSLS	News Release200	ReShape Lifesciences(TM) Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update
2025-05-07 08:31	UU:RSLS	News Release200	ReShape Lifesciences Announces 1-for-25 Reverse Stock Split
2025-05-02 08:31	UU:RSLS	News Release200	ReShape Lifesciences(TM) Presents Pre-clinical Data on Its Proprietary Diabetes Neuromodulation Device at the 12th Annual Minnesota Neuromodulation Symposium
2025-04-28 08:31	UU:RSLS	News Release200	ReShape Lifesciences(TM) Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon System
2025-04-21 08:31	UU:RSLS	News Release200	ReShape Lifesciences(TM) Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology
2025-04-09 16:05	UU:RSLS	News Release200	ReShape Lifesciences(TM) Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market
2025-04-07 16:05	UU:RSLS	News Release200	ReShape Lifesciences(TM) Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update
2025-03-10 08:31	UU:RSLS	News Release200	ReShape Lifesciences(TM) Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology
2025-02-25 08:31	UU:RSLS	News Release200	ReShape Lifesciences(TM) Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band(TM) 2.0 FLEX
2025-02-15 23:18	UU:RSLS	News Release200	ReShape Lifesciences(TM) Announces Pricing of Upsized $6.0 Million Public Offering
2025-02-03 08:31	UU:RSLS	News Release200	ReShape Lifesciences(TM) Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology
2025-01-13 08:31	UU:RSLS	News Release200	ReShape Lifesciences(TM) Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
2024-11-14 16:05	UU:RSLS	News Release200	ReShape Lifesciences(TM) Reports Third Quarter Ended September 30, 2024 Financial Results and Provides Corporate Update
2024-11-12 16:05	UU:RSLS	News Release200	ReShape Lifesciences(TM) to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
2024-11-12 08:31	UU:RSLS	News Release200	ReShape Lifesciences(TM) Receives Health Canada Approval for its Next-Generation Lap-Band(TM) 2.0 FLEX
2024-11-11 08:31	UU:RSLS	News Release200	ReShape Lifesciences(TM) Receives NIH Supplementary Grant with the University of Southern California's Center for Autonomic Nerve Recording and Stimulation Systems (CARSS) to Further Develop Next-Generation Electrodes for ReShape's Proprietary Diabetes Bl
2024-09-19 08:31	UU:RSLS	News Release200	ReShape Lifesciences Announces 1-for-58 Reverse Stock Split